85 related articles for article (PubMed ID: 23167531)
1. Absorption, metabolism and excretion of darexaban (YM150), a new direct factor Xa inhibitor in humans.
Hashimoto T; Suzuki K; Kihara Y; Iwatsubo T; Miyashita A; Heeringa M; Onkels H; Groenendaal D; Verheggen F; van Marle S; Usui T
Xenobiotica; 2013 Jun; 43(6):534-47. PubMed ID: 23167531
[TBL] [Abstract][Full Text] [Related]
2. Biochemical and pharmacological profile of darexaban, an oral direct factor Xa inhibitor.
Iwatsuki Y; Sato T; Moritani Y; Shigenaga T; Suzuki M; Kawasaki T; Funatsu T; Kaku S
Eur J Pharmacol; 2011 Dec; 673(1-3):49-55. PubMed ID: 22040919
[TBL] [Abstract][Full Text] [Related]
3. Identification of UDP-glucuronosyltransferases responsible for the glucuronidation of darexaban, an oral factor Xa inhibitor, in human liver and intestine.
Shiraga T; Yajima K; Suzuki K; Suzuki K; Hashimoto T; Iwatsubo T; Miyashita A; Usui T
Drug Metab Dispos; 2012 Feb; 40(2):276-82. PubMed ID: 22031623
[TBL] [Abstract][Full Text] [Related]
4. The pharmacokinetics of darexaban (YM150), an oral direct factor Xa inhibitor, are not affected by ketoconazole, a strong inhibitor of CYP3A and P-glycoprotein.
Groenendaal D; Strabach G; Garcia-Hernandez A; Kadokura T; Heeringa M; Mol R; Eltink C; Onkels H
Clin Pharmacol Drug Dev; 2014 May; 3(3):194-201. PubMed ID: 27128609
[TBL] [Abstract][Full Text] [Related]
5. Effect of food on the pharmacokinetics of darexaban, an oral direct factor Xa inhibitor, in healthy Japanese subjects.
Kadokura T; Taniuchi Y; Inoue H; Saito M; Iwahana M; Yamada S; Urae A; Nakamura M
Int J Clin Pharmacol Ther; 2013 Mar; 51(3):200-6. PubMed ID: 23211396
[TBL] [Abstract][Full Text] [Related]
6. Darexaban (YM150), an oral direct factor Xa inhibitor, has no effect on the pharmacokinetics of digoxin.
Kadokura T; Groenendaal D; Heeringa M; Mol R; Verheggen F; Garcia-Hernandez A; Onkels H
Eur J Drug Metab Pharmacokinet; 2014 Mar; 39(1):1-9. PubMed ID: 23754514
[TBL] [Abstract][Full Text] [Related]
7. Plasma factor Xa inhibition can predict antithrombotic effects of oral direct factor Xa inhibitors in rabbit atherothrombosis models.
Funatsu T; Yamashita A; Kaku S; Iwatsuki Y; Asada Y
Thromb Haemost; 2012 Nov; 108(5):896-902. PubMed ID: 23052641
[TBL] [Abstract][Full Text] [Related]
8. Clinical pharmacokinetics, pharmacodynamics, safety and tolerability of darexaban, an oral direct factor Xa inhibitor, in healthy Caucasian and Japanese subjects.
Kadokura T; Kashiwa M; Groenendaal D; Heeringa M; Mol R; Verheggen F; Garcia-Hernandez A; Onkels H
Biopharm Drug Dispos; 2013 Nov; 34(8):431-41. PubMed ID: 23929659
[TBL] [Abstract][Full Text] [Related]
9. The pharmacokinetics of darexaban are not affected to a clinically relevant degree by rifampicin, a strong inducer of P-glycoprotein and CYP3A4.
Groenendaal D; Strabach G; Garcia-Hernandez A; Kadokura T; Heeringa M; Mol R; Eltink C; Onkels H
Br J Clin Pharmacol; 2013 Feb; 75(2):440-9. PubMed ID: 22642721
[TBL] [Abstract][Full Text] [Related]
10. Identification of enzymes responsible for the N-oxidation of darexaban glucuronide, the pharmacologically active metabolite of darexaban, and the glucuronidation of darexaban N-oxides in human liver microsomes.
Shiraga T; Yajima K; Teragaki T; Suzuki K; Hashimoto T; Iwatsubo T; Miyashita A; Usui T
Biol Pharm Bull; 2012; 35(3):413-21. PubMed ID: 22382330
[TBL] [Abstract][Full Text] [Related]
11. Novel oral anticoagulants: focus on the direct factor Xa inhibitor darexaban.
Apostolakis S; Lip GY
Expert Opin Investig Drugs; 2012 Jul; 21(7):1057-64. PubMed ID: 22616561
[TBL] [Abstract][Full Text] [Related]
12. Discovery of N-[2-hydroxy-6-(4-methoxybenzamido)phenyl]-4- (4-methyl-1,4-diazepan-1-yl)benzamide (darexaban, YM150) as a potent and orally available factor Xa inhibitor.
Hirayama F; Koshio H; Ishihara T; Hachiya S; Sugasawa K; Koga Y; Seki N; Shiraki R; Shigenaga T; Iwatsuki Y; Moritani Y; Mori K; Kadokura T; Kawasaki T; Matsumoto Y; Sakamoto S; Tsukamoto S
J Med Chem; 2011 Dec; 54(23):8051-65. PubMed ID: 21995444
[TBL] [Abstract][Full Text] [Related]
13. Absorption, distribution, metabolism and excretion of YM466, a novel factor Xa inhibitor, in rats.
Mano Y; Sonoda T; Nakamura E; Usui T; Kamimura H
Biopharm Drug Dispos; 2004 Sep; 25(6):253-60. PubMed ID: 15334624
[TBL] [Abstract][Full Text] [Related]
14. Antithrombotic and anticoagulant effects of direct factor Xa inhibitor darexaban in rat and rabbit models of venous thrombosis.
Kaku S; Uemura T; Saitoh M; Suzuki K; Iwatsuki Y; Funatsu T; Kawasaki T
Eur J Pharmacol; 2013 Jan; 699(1-3):40-7. PubMed ID: 23200896
[TBL] [Abstract][Full Text] [Related]
15. Absorption, distribution and excretion of [carbonyl-14C]mosapride citrate after a single oral administration in rats, dogs and monkeys.
Matsumoto S; Tagawa M; Amejima H; Nakao M; Kagemoto A; Fujii T; Miyazaki H; Sekine Y
Arzneimittelforschung; 1993 Oct; 43(10):1084-94. PubMed ID: 8267675
[TBL] [Abstract][Full Text] [Related]
16. Comparative metabolism of 14C-labeled apixaban in mice, rats, rabbits, dogs, and humans.
Zhang D; He K; Raghavan N; Wang L; Mitroka J; Maxwell BD; Knabb RM; Frost C; Schuster A; Hao F; Gu Z; Humphreys WG; Grossman SJ
Drug Metab Dispos; 2009 Aug; 37(8):1738-48. PubMed ID: 19420130
[TBL] [Abstract][Full Text] [Related]
17. RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome.
Steg PG; Mehta SR; Jukema JW; Lip GY; Gibson CM; Kovar F; Kala P; Garcia-Hernandez A; Renfurm RW; Granger CB;
Eur Heart J; 2011 Oct; 32(20):2541-54. PubMed ID: 21878434
[TBL] [Abstract][Full Text] [Related]
18. Novel strategy to boost oral anticoagulant activity of blood coagulation enzyme inhibitors based on biotransformation into hydrophilic conjugates.
Ishihara T; Koga Y; Mori K; Sugasawa K; Iwatsuki Y; Hirayama F
Bioorg Med Chem; 2014 Nov; 22(22):6324-32. PubMed ID: 25438755
[TBL] [Abstract][Full Text] [Related]
19. Absorption, metabolism and excretion of [(14)C]mirabegron (YM178), a potent and selective β(3)-adrenoceptor agonist, after oral administration to healthy male volunteers.
Takusagawa S; van Lier JJ; Suzuki K; Nagata M; Meijer J; Krauwinkel W; Schaddelee M; Sekiguchi M; Miyashita A; Iwatsubo T; van Gelderen M; Usui T
Drug Metab Dispos; 2012 Apr; 40(4):815-24. PubMed ID: 22269146
[TBL] [Abstract][Full Text] [Related]
20. Absorption, metabolism, and excretion of [14C]imidafenacin, a new compound for treatment of overactive bladder, after oral administration to healthy male subjects.
Ohmori S; Miura M; Toriumi C; Satoh Y; Ooie T
Drug Metab Dispos; 2007 Sep; 35(9):1624-33. PubMed ID: 17567733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
